Documents

NCI-H69/LX4

96042329

Pricing and availability is not currently available.

biological source

human lung

growth mode

Aggregates in suspension

karyotype

Not specified

morphology

Not specified

products

Not specified

receptors

Not specified

application(s)

cell culture | mammalian: suitable

relevant disease(s)

cancer

shipped in

dry ice

storage temp.

−196°C

Related Categories

Cell Line Origin

Human Caucasian small cell lung carcinoma, drug-resistant

Cell Line Description

NCI-H69/LX4 has been established by exposure of the parent line, H69 (Sigma Catalogue number. 91091802) to doxorubicin, also known as adriamycin. The line hyperexpresses P-glycoprotein and demonstrates a multidrug resistant drug accumulation deficit. It is recommended to culture the cells without drug after resuscitation until the first passage.

Application

Analysis of acquired drug-resistance, study of small cell lung cancer

DNA Profile

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 12
D16S539: 11
D5S818: 11,13
D7S820: 9
THO1: 8,9
TPOX: 10
vWA: 16,17

Culture Medium

RPMI + 2mM Glutamine + 0.4μg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).

Subculture Routine

Split sub-confluent cultures (70-80%) by repeated pipetting of aggregates or scraping; 5% CO2; 37°C

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

RIDADR

NONH for all modes of transport

Certificate of Analysis
Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.